(R)-tert-butyl (1-(4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pent-4-en-2-yl)carbamate | 1451370-51-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: (R)-tert-butyl (1-(4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pent-4-en-2-yl)carbamate
• 英文别名: tert-butyl N-[(2R)-1-(4-chloro-5-iodopyrrolo[2,3-d]pyrimidin-7-yl)pent-4-en-2-yl]carbamate
• CAS: 1451370-51-6
• 化学式: C₁₆H₂₀ClIN₄O₂
• 分子量: 462.718
• InChiKey: CNQPKDQMJKJBSY-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  69
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-tert-butyl (1-(4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pent-4-en-2-yl)carbamate 、 (R)-tert-butyl (1-(4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)but-3-en-2-yl)carbamate 以obtaining the title compound (2.743 g) as a light-yellow solid的产率得到(R)-tert-butyl (1-(4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pent-4-en-2-yl)(methyl)carbamate
  参考文献：
  名称：

  NOVEL QUINOLINE -SUBSTITUTED COMPOUND

  摘要：

  本发明旨在提供一种具有EGFR抑制作用和细胞生长抑制作用的新型化合物，以及基于EGFR抑制作用的预防和/或治疗癌症的药物。本发明提供以下公式（I）所表示的化合物或其盐。

  公开号：

  US20160194332A1

文献信息

• QUINOLYL PYRROLO PYRIMIDYL CONDENSED-RING COMPOUND AND SALT THEREOF
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：US20140057899A1

  公开（公告）日：2014-02-27

  The present invention provides a new compound that has an inhibitory action against EGFR and that has cell growth inhibitory effects. The present invention further provides a pharmaceutical preparation useful for preventing and/or treating cancer, based on the EGFR inhibitory effect of the compound. A compound represented by the following Formula (I) or a salt thereof.

  本发明提供了一种对EGFR具有抑制作用并具有细胞生长抑制作用的新化合物。本发明还提供了一种药物制剂，可根据该化合物的EGFR抑制作用用于预防和/或治疗癌症。由下式（I）表示的化合物或其盐。
• METHOD FOR PRODUCNG TRICYCLIC COMPOUND, AND TRICYCLIC COMPOUND CAPABLE OF BEING PRODUCED BY SAID PRODUCTION METHOD
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US20160115172A1

  公开（公告）日：2016-04-28

  An object of the present invention is to provide a method for reproducibly producing a pyrrolopyrimidine ring-containing tricyclic compound in high yield with reduced formation of by-products, and to provide a novel tricyclic compound capable of being obtained by this production method. The present invention provides a method for producing a compound represented by Formula (1) or a salt thereof, the method comprising the steps of: (I) causing an organic borane reagent to act on a compound represented by Formula (2) or a salt thereof, and (II) performing an intramolecular cyclization reaction of the reaction product of step (I) above using a zerovalent palladium catalyst in the presence of an alkali metal hydroxide.

  本发明的目的是提供一种方法，以高收率可重复地生产含有吡咯吡嘧啶环的三环化合物，并减少副产物的形成，并提供一种能够通过这种生产方法获得的新型三环化合物。本发明提供了一种制备由式（1）或其盐所表示的化合物的方法，该方法包括以下步骤：（I）使有机硼试剂作用于由式（2）或其盐所表示的化合物，和（II）在碱金属氢氧化物存在下，使用零价钯催化剂对步骤（I）中的反应产物进行分子内环化反应。
• QUINOLYLPYRROLOPYRIMIDYL FUSED-RING COMPOUND OR SALT THEREOF
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP2722332B1

  公开（公告）日：2016-04-20
• NOVEL QUINOLINE-SUBSTITUTED COMPOUND
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US20170101414A1

  公开（公告）日：2017-04-13

  An object to be achieved by the present invention is to provide a novel compound having EGFR inhibitory effects and cell growth inhibitory effects, as well as a medication useful for the prevention and/or treatment of cancer based on the EGFR inhibitory effects. The present invention provides a compound represented by Formula (I) below, or a salt thereof.
• US8889666B2
  申请人：——

  公开号：US8889666B2

  公开（公告）日：2014-11-18